Travere Therapeutics, Inc.
TVTX
$25.16
-$0.91-3.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 69.06% | 31.59% | -9.95% | 22.15% | 48.25% |
| Total Depreciation and Amortization | 9.48% | 5.88% | 7.58% | 8.64% | 4.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.67% | 198.26% | -57.36% | -90.31% | 695.87% |
| Change in Net Operating Assets | 76.20% | -420.13% | 209.84% | 88.91% | -1,961.68% |
| Cash from Operations | 111.81% | -18.12% | 15.97% | -5.63% | 66.18% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -87.68% | 151.36% | -274.29% | 60.76% | -72.65% |
| Cash from Investing | -88.25% | 151.41% | -274.11% | 61.22% | -72.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -52.86% | -96.96% | 24,356.04% | -56.31% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash from Financing | -60.33% | -97.33% | 302,332.61% | -94.12% | 248.95% |
| Foreign Exchange rate Adjustments | 255.66% | 156.85% | -312.80% | 515.60% | 62.80% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 294.32% | -84.81% | 437.30% | 137.57% | 26.57% |